Silence Therapeutics PLC 8-K filings

Silence Therapeutics plc has successfully priced an upsized underwritten public offering of American Depositary Shares, raising approximately $175 million to advance its siRNA therapies.

Silence Therapeutics plc reported positive topline results from the Phase 2 SANRECO trial of divesiran for polycythemia vera, meeting primary and secondary endpoints and supporting advancement to Phase 3.

Silence Therapeutics plc announced its second quarter 2026 financial and business results, highlighting progress in its Divesiran and SLN312 programs and a reduced net loss.

Silence Therapeutics plc has amended its previous Form 8-K filing to provide further details on the separation agreement with former executive Craig Tooman, including updated compensation and benefits.

Silence Therapeutics plc successfully passed all nine resolutions at its 2026 Annual General Meeting held on June 16, 2026.

Silence Therapeutics presented follow-up data from its Phase 1 SANRECO study of divesiran for polycythemia vera, highlighting durable efficacy and quality-of-life improvements.

Silence Therapeutics plc has entered into a new Open Market Sale Agreement with Jefferies LLC, replacing a prior agreement, to potentially sell American Depositary Shares (ADSs) from time to time.

Silence Therapeutics plc reported Q1 2026 financial results, highlighting progress in its Phase 2 SANRECO trial for divesiran, with topline results anticipated in August 2026.

Silence Therapeutics announced its full year 2025 financial results with a significantly increased net loss, alongside key clinical and pipeline updates.

Silence Therapeutics plc filed an amendment to its 8-K, disclosing the compensation package for interim CEO Iain Ross and new committee appointments for director James Ede-Golightly.

Silence Therapeutics plc announced the immediate appointment of its Executive Vice President and Chief Financial Officer, Rhonda Hellums, to its Board of Directors.

Silence Therapeutics announced the departure of its CEO, Craig Tooman, and the appointment of Chairman Iain Ross as interim CEO, alongside a new board appointment.

Silence Therapeutics announced its third quarter 2025 financial results, highlighted by the full enrollment of its SANRECO Phase 2 study for divesiran in polycythemia vera and a cash runway into 2028.

Silence Therapeutics has completed patient enrollment in its SANRECO Phase 2 study of divesiran for polycythemia vera, with topline results expected in Q3 2026.

Silence Therapeutics plc announced the immediate resignation of Director Michael Davidson, leading to a reduction in board size and a new committee appointment.

Silence Therapeutics reported its second quarter 2025 financial results, highlighting progress in its clinical trials and reiterating its cash runway guidance into 2028.

Silence Therapeutics plc announced that all thirteen resolutions, including director re-appointments and auditor ratifications, were duly passed by shareholders at its 2025 Annual General Meeting held on June 26, 2025.

Silence Therapeutics announced its Q1 2025 financial results, highlighting progress in clinical trials and extending its cash runway into 2028 through cost-saving initiatives.

Silence Therapeutics announced the appointment of Tim McInerney to its Board of Directors and the upcoming retirement of James Ede-Golightly at the 2025 Annual General Meeting.

Silence Therapeutics announced its full year 2024 financial results, provided a business update, and extended its cash runway into 2027 by prioritizing key programs and seeking a partner for zerlasiran Phase 3 development.

Silence Therapeutics will now file as a U.S. domestic issuer, requiring more detailed and prompt reporting to the SEC.